磁共振成像T1增强对比信号强度是硬纤维瘤型纤维瘤病中伊马替尼治疗的预后指标。
MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis.
作者信息
Zhu Hui Ci, Xu Shi Xing, Li Xiao Ting, Guan Zhen, Li Shu, Sun Ying-Shi
机构信息
Department Radiology, Peking University Cancer Hospital, Beijing, China.
Department Plastic Surgery No.6, Plastic Surgery Hospital, Beijing, China.
出版信息
Front Oncol. 2021 Mar 15;11:615986. doi: 10.3389/fonc.2021.615986. eCollection 2021.
OBJECTIVE
To investigate the efficiency of pre-therapy magnetic resonance imaging (MRI) features in predicting the prognosis of desmoid-type fibromatosis patients treated with imatinib.
MATERIALS AND METHODS
A total of 38 desmoid-type fibromatosis patients treated with imatinib were collected in this retrospective study. The high signal intensity on pre-therapy MRI was evaluated on axial T2 and T1 contrast-enhanced sequences with fat suppression. Cox regression and Kaplan-Meier analyses explored the correlation between clinical or radiographic characteristics and progression-free survival (PFS).
RESULTS
Hyperintense T1 contrast enhancement (CE) proportion (≥ 75%) was identified as an independent predictor for PFS. Patients with hyperintense T1 CE proportion <75% demonstrated no progression, while patients with hyperintense T1 CE proportion ≥75% demonstrated a progression rate of 78.4%.
CONCLUSION
Hyperintense T1 CE proportion in the tumor is a potential predictor of disease progression in patients with desmoid-type fibromatosis treated with imatinib. Hyperintense T1 CE proportion <75% indicates progression-free during treatment.
目的
探讨治疗前磁共振成像（MRI）特征对伊马替尼治疗的韧带样型纤维瘤病患者预后的预测效能。
材料与方法
本回顾性研究共纳入38例接受伊马替尼治疗的韧带样型纤维瘤病患者。在轴位T2加权像及脂肪抑制的T1加权像增强序列上评估治疗前MRI的高信号强度。采用Cox回归分析和Kaplan-Meier分析探讨临床或影像学特征与无进展生存期（PFS）之间的相关性。
结果
T1加权像增强（CE）高信号比例（≥75%）被确定为PFS的独立预测因子。T1加权像CE高信号比例<75%的患者无疾病进展，而T1加权像CE高信号比例≥75%的患者疾病进展率为78.4%。
结论
肿瘤T1加权像CE高信号比例是伊马替尼治疗的韧带样型纤维瘤病患者疾病进展的潜在预测因子。T1加权像CE高信号比例<75%表明治疗期间无疾病进展。
Zotero 插件